
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is poised for significant revenue growth, with projections indicating a substantial sales acceleration in 2026, where Obe-cel and other therapies could drive revenue estimates to $167 million, reflecting a 220% year-over-year increase. The company's guidance for Aucatzyl revenues suggests a robust 60-80% increase in 2026, bolstered by the expansion of its network to over 80 locations. Additionally, the rising adoption rates of CAR-T therapies in the UK, coupled with favorable reimbursement changes for bispecifics, underpin the positive outlook for Autolus Therapeutics's financial performance.
Bears say
Autolus Therapeutics PLC has experienced a significant decline in its stock price, dropping approximately 48% since July 2025, primarily due to stagnant revenue growth in its lead product, Aucatzyl, which is constrained by manufacturing capacity issues following a change in Medicare guidelines. The company's financial outlook is further complicated by the necessity for an estimated $1 billion in additional capital through 2038, alongside concerns about its cash runway extending only until 2027. Additionally, risks related to the efficacy and safety of its clinical programs, regulatory decisions, and competitive pressures could impact the company’s ability to meet its strategic goals and financial projections.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares